**Concept Development Form**

Please ensure that your concept addresses the majority of points noted in the Concept Development Form below. A checklist is provided below to aid investigators in preparing their concept for submission to ANZGOG. Concepts are reviewed by the ANZGOG Research Advisory Committee and the ANZGOG Consumer Research Panel.

Email your completed concept development form to [john.andrews@anzgog.org.au](mailto:john.andrews@anzgog.org.au)

If you have any questions, please email John Andrews at [john.andrews@anzgog.org.au](mailto:john.andrews@anzgog.org.au)

**Please indicate your intention:**

I am submitting this concept for oral presentation at the ANZGOG ASM 2024.

I am submitting this concept for further development with the relevant Tumour Working Group.

|  |  |
| --- | --- |
| Date of submission: |  |

|  |  |
| --- | --- |
| Concept Title |  |
| Study Phase | 🞎 Phase I 🞎 Phase II 🞎 Phase III 🞎 Other |
| Cancer Type | 🞎 Ovarian 🞎 Cervical 🞎 Endometrial 🞎 Other |
| Background and Significance |  |
| Study Summary | Aims: |
|  | Hypothesis: |
|  | Objectives: |
|  | Endpoints: |
| Subject Population |  |
| Study Procedures |  |
| Statistical Considerations |  |
| Feasibility |  |
| Bio-specimen Collection /Translational Research |  |
| Quality of Life Assessment |  |
| Health Economics |  |
| Funding | 🞎 Budget developed  🞎 Funded 🞎 Pending 🞎 None  Funding options for consideration:  🞎 NHMRC/CA 🞎 Local Institution 🞎 ANZGOG 🞎 Other  ………………………………………………………………………….. |
| Drugs and sponsorship | Drug: Pharma Co:  Will pharma provide drug? Yes 🞎 No 🞎 N/A 🞎  Pharma contact information: |
| Lay summary for consumer review (250 words) |  |
| List of other collaborative trial groups involved |  |
| Protocol | In development: 🞎 Yes 🞎 No  Assistance required from ANZGOG to develop further: 🞎 Yes 🞎 No |
| ANZGOG involvement requested | 🞎 Multi-centre trial with ANZGOG Study Identification:  🞎Other research study seeking ANZGOG Study Identification:  Describe …………………………………………………. …………………………..  🞎 limited or single centre study …………………………………………….………  🞎 Unknown, to be determined |

**Study Chair**

|  |  |
| --- | --- |
| Name: | Organisation: |
| Speciality: | Email: |
| Phone: | Mobile: |

**Investigator/s**

Investigators’ names should be supplied in the surname-last format with the initial in capital. Institutional affiliations should be indicated with superscript numbers following the author name.

All affiliations should contain institution, city and country.

Example:

J Smith1, S Doe1

1 Department of Oncology, XYZ Hospital, Sydney, Australia

|  |
| --- |
| **Investigator/s (list all)** |
| **Affiliations (list all the institutions)** |

# Guidelines for completing your concept

**CONCEPT TITLE**

* Should be in the PICO format (ie the title should hold information on the participants, Intervention and Comparison groups, and the Outcomes of the trial).

**BACKGROUND AND SIGNIFICANCE**

* Have you addressed the scientific validity?
* Is it an important question?
* Size of population defined?
* Sufficient rationale to proceed?
* Is it clinically relevant?
* Have you searched ANZCTR and other registries? [www.anzctr.org.au](http://www.anzctr.org.au)

**STUDY SUMMARY**

* **Aims:**i. Are they clearly stated?
* **Trial objectives:**ii. Do they match aims?
* **Hypotheses:**

iii. Are they clearly stated?

iv. Do they match aims and objectives?

* **Endpoints:**i. Are they measurable?

ii. Are they suitable to answer trial questions?

**STUDY DESIGN AND STATISTICS**

* Phase of study?
* Is design appropriate to address the question?
* Are treatment arms clearly described?
* What is the sample size estimate?
* Is the sample size justified in terms of primary endpoint?
* Is the study likely to detect a clinically significant difference?
* Has a statistician reviewed the study design?
* Is the study feasible? Outline the proposed sources of subjects and estimated recruitment rates.

**SUBJECT POPULATION**

* Target population and setting should be described briefly. Main inclusion criteria – are they clearly stated and clinically relevant?

**STUDY INTERVENTION**

* Briefly describe actions to be taken

**FUNDING**

* Is there any financial support for the study?

**TRANSLATIONAL RESEARCH**

* Is there a translational research component? Briefly describe any rationale, pilot data and methods, including anticipated biospecimen collection, if known.
* TR-ANZGOG Network Laboratory support is available to assist with collection, processing and storing biospecimens for ANZGOG trials, and provision of specialised media as required.
* The TR-ANZGOG Biospecimen Processing Manual (available upon request to the Project Manager, TR-ANZGOG), outlines flexible, standard processing recommendations for a variety of biospecimen types. Please liaise with the Project Manager, TR-ANZGOG [Claire.Davies@anzgog.org.au](mailto:Claire.Davies@anzgog.org.au) regarding trial requirements, if applicable.

**OTHER**

* Have QOL and Health Economics assessments been included?
* Is there collaborative support from other trials groups